Medicinal Chemistry Hit-to-Lead (H2L) 2

You are here:

Charnwood Molecular worked with a UK Biotech Company, supporting with 4 FTEs, over a 12-month period. Read below to learn more:

  • European biotech company (Rare disease target) 
  • Supported with 2 FTEs for 12 months
  • Elaboration of existing hits to elucidate SAR
  • Rational design to deliver drug-like compounds
  • Compounds screened by client (SPR and cell assays) 
  • >200 compounds prepared over four series
  • Highly potent compounds with good ADME properties, clear SAR and in vivo efficacy

We are flexible in our approach – some clients wish to keep screening in-house, others ask that we manage and drive this process. 

Our goal is to provide a tailored service to suit clients’ aspirations and budget, but with a focus on excellence of delivery at all stages.

Share this post:

From the same category: